Astronics
Astronics' revenue rose 8.4% to $862 million in fiscal 2025. Its operating margin was 8.9%, up from 3.3% a year earlier. Free cash flow was $43 million, up 94.8%. The diluted share count rose 4.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Astronics does
Astronics makes technology for the aerospace, defense and electronics industries. Its products include electrical power generation and distribution, seat motion systems, lighting and safety systems, avionics, aircraft structures and automated test systems. It has main operations in the U.S., Canada, France and Germany, plus engineering offices in Ukraine and India.
It has two segments. Aerospace sells to aircraft makers, their suppliers, airlines and the U.S. Department of Defense. In 2025 its sales were split 75% to commercial transport, 15% to military aircraft, 9% to general aviation and 1% to other markets. Test Systems designs and maintains automated test systems for aerospace and defense, communications and mass transit, usually in large, multi-year projects.
Boeing is its one major customer, at 10.4% of 2025 sales. The company had about 2,700 full-time employees at the end of 2025.
Its biggest risks, as it describes them
- Losing Boeing as a customer or a big drop in its orders.
- Cycles in aerospace demand tied to Boeing and Airbus production rates.
- Tariffs, trade rules and economic conditions that can swing results.
- Taking on more debt for working capital or acquisitions.
- Most Aerospace sales come from day-to-day or one-year orders, not long-term commitments.
Income statement
From fiscal 2016 to 2025, earnings per share fell 5.9% a year and net income 5.4% a year, as new shares raised the share count by 6% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 30 | 14 | 5 | 9 | 18 |
| Debt incl. finance leases | 163 | 164 | 168 | 169 | 334 |
| Net debt (negative means net cash) | 133 | 150 | 164 | 160 | 316 |
| Net debt to EBITDA | 402.8x | — | 8.4x | 3.1x | 3.2x |
| Debt to equity | 0.6x | 0.7x | 0.7x | 0.7x | 2.4x |
| Interest coverage | −4.8x | −4.0x | −0.4x | 1.4x | 8.5x |
| Current ratio | 2.9x | 2.4x | 2.7x | 2.7x | 3.1x |
| Quick ratio | 1.5x | 1.2x | 1.4x | 1.4x | 1.7x |
Cash flow
Projections
Project Astronics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Astronics says to expect
- Full year 2026: revenue
Astronics expects to set another annual sales record in 2026 with revenue estimated to be $1.02 billion to $1.04 billion for the year, representing growth of 19.5% over 2025 at the midpoint. Fourth quarter sales are expected to be $255 million to $275 million.
- Full year 2026: capital expenditures
Planned capital expenditures in 2026 are expected to be in the range of $25 million to $30 million driven largely by costs associated with the Seattle operation consolidation, which concluded in the third quarter.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Astronics shares on the open market, and 1 insider sold $518,238.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 1, 2025 | James MulatoPres Astronics Test Systems | Sold | 9,734 | $53.24 | $518,238 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 7 of 9 | 7 of 9 |
| Rule of 40 | 24.3% | 18.2% | 13.4% |
| Altman Z'' | 4.24 | 4.66 | 4.74 |
| Accruals ratio | −0.4% | −7.3% | −6.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 7 of 9 | 7 of 9 |
Compare
Put Astronics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Astronics | FY25 | 8.4% | 8.9% | 5.0% | 16.1% | 3.2x | 7 | |
| Ducommun | FY25 | 4.9% | −4.3% | −5.9% | −3.1% | — | 5 | Compare |
| VSE | FY25 | 41.5% | 8.1% | 0.5% | 4.5% | 1.7x | 6 | Compare |
| Cadre Holdings | FY25 | 7.5% | 11.0% | 9.3% | 10.4% | 2.2x | 5 | Compare |
| Rocket Lab | FY25 | 38.0% | −38.0% | −53.5% | −30.2% | — | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 633 | 624 | 803 | 773 | 503 | 445 | 535 | 689 | 795 | 862 |
| Revenue growth | −8.6% | −1.4% | 28.6% | −3.8% | −35.0% | −11.5% | 20.2% | 28.9% | 15.4% | 8.4% |
| Gross profit | 160 | 137 | 181 | 156 | 97 | 65 | 72 | 174 | 220 | 258 |
| Research and development | 89 | 95 | 114 | 109 | 40 | 43 | 48 | 54 | 52 | 44 |
| Operating income | 75 | 32 | 64 | 2 | −101 | −29 | −30 | −7 | 26 | 76 |
| Net income | 48 | 20 | 47 | 52 | −116 | −26 | −36 | −26 | −16 | 29 |
| Diluted EPS (US$) | 1.40 | 0.58 | 1.41 | 1.60 | −3.76 | −0.82 | −1.11 | −0.80 | −0.46 | 0.81 |
| Diluted shares (millions) | 34 | 34 | 33 | 32 | 31 | 31 | 32 | 33 | 35 | 36 |
| Cash flow | ||||||||||
| Cash from operations | 49 | 38 | 55 | 43 | 37 | −6 | −28 | −24 | 31 | 75 |
| Capital expenditure | 13 | 14 | 16 | 12 | 8 | 6 | 8 | 8 | 8 | 32 |
| Free cash flow | 36 | 24 | 39 | 31 | 30 | −12 | −36 | −32 | 22 | 43 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 18 | 32 | 0 | 51 | 8 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 114 | 0 | 29 | 0 | 0 | 0 | 0 | 0 | 22 |
| Stock-based compensation | 2 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | 9 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 18 | 18 | 17 | 32 | 40 | 30 | 14 | 5 | 9 | 18 |
| Debt incl. finance leases | 148 | 272 | 234 | 188 | 173 | 163 | 164 | 168 | 169 | 334 |
| Total assets | 604 | 736 | 775 | 783 | 620 | 609 | 615 | 634 | 649 | 707 |
| Total liabilities | 267 | 406 | 388 | 394 | 349 | 352 | 375 | 384 | 393 | 567 |
| Shareholders' equity | 337 | 330 | 387 | 389 | 270 | 257 | 240 | 250 | 256 | 140 |
| Margins and ratios | ||||||||||
| Gross margin | 25.2% | 22.0% | 22.5% | 20.2% | 19.3% | 14.7% | 13.4% | 25.3% | 27.7% | 29.9% |
| Operating margin | 11.8% | 5.1% | 7.9% | 0.2% | −20.0% | −6.4% | −5.6% | −1.0% | 3.3% | 8.9% |
| Net margin | 7.7% | 3.1% | 5.8% | 6.7% | −23.0% | −5.8% | −6.7% | −3.8% | −2.0% | 3.4% |
| Free cash flow margin | 5.7% | 3.9% | 4.8% | 4.0% | 5.9% | −2.6% | −6.7% | −4.6% | 2.8% | 5.0% |
| Rule of 40 (growth + FCF margin) | −2.9% | 2.5% | 33.4% | 0.2% | −29.0% | −14.1% | 13.5% | 24.3% | 18.2% | 13.4% |
| Return on capital | 11.5% | 4.8% | 9.6% | 0.2% | −16.8% | −5.7% | −6.1% | −1.3% | 5.0% | 16.1% |
| Return on equity | 15.2% | 5.9% | 13.1% | 13.4% | −35.1% | −9.7% | −14.4% | −10.8% | −6.4% | 14.8% |
| Return on assets | 8.0% | 2.9% | 6.2% | 6.7% | −16.5% | −4.2% | −5.8% | −4.2% | −2.5% | 4.3% |
| Net debt to EBITDA | 1.3x | 4.3x | 2.2x | 4.5x | — | 402.8x | — | 8.4x | 3.1x | 3.2x |